Vedolizumab: A novel treatment for ipilimumab-induced colitis

BMJ Case Reports

Volumn 2016, Issue , 2016, Pages

  Hsieh, Amy Hsin Chieh ^a   Ferman, Mutaz ^a   Brown, Michael P ^a   Andrews, Jane M ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CALGRANULIN; IPILIMUMAB; NIVOLUMAB; PREDNISOLONE; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BLOODY DIARRHEA; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COLITIS; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FECES ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MELANOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; TUMOR BIOPSY; CHEMICALLY INDUCED; PATHOLOGY; SKIN NEOPLASMS; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS; GASTROINTESTINAL AGENTS; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS;

EID: 84983685305     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2016-216641     Document Type: Article

References (14)

1. Robert C, Long G, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30.
2. Weber JS, De?Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 14: 375-84.
3. Hodi FS, O?Day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-25.
5. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015; 4: 560-75.
6. Pagès C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013; 23: 227-30.
7. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522-30.
8. Dean KE, Hikaka J, Huakau JT, et al. Infliximab or cyclosporine for acute severe ulcerative colitis. J Gastroenterol Hepatol 2012; 27: 487-92.
9. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events, and kinetic of response with ipilimumab. J Clin Oncol 2012; 30: 2691-7.
10. Yapali S, Hamzaoglu HO. Anti-TNF treatment in inflammatory bowel disease. Ann Gastroenterol 2007; 21: 48-53.
11. Laharie D, Bourreile A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-15.
12. Guo Y, Lu N, Bai A, et al. Clinical use, and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int 2013; 2013: 581631.
13. Mclean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis, and Crohn?s disease. Immunotherapy 2012; 4: 883-98.
14. Lau MSY, Tsai HH. Review of vedolizumab for treatment of ulcerative colitis. World J Gastrointest Pharmacol Ther 2016; 7: 107-11.